Overview

Gender

male

Investor Type

Investment Partner

Frank Holler is an active investor and successful entrepreneur. He previously served as President & CEO of Xenon Pharmaceuticals Inc., a private genomics-based drug development company, from 1999 to 2003; President & CEO of ID Biomedical from 1991 to 1998, a vaccine development company sold to GlaxoSmithKline in 2005 for $1.6 billion; and a founding director of Angiotech Pharmaceuticals, a TSX/ NASDAQ listed biotechnology company from 1992 to 1997. Prior to working in biotechnology and healthcare, Mr. Holler was a Vice-President of Investment Banking with Merrill Lynch Canada and Wood Gundy Inc. (now CIBC World Markets).

Frank presently serves on the board of directors of Protox Therapeutics (Chairman), Emerillon Therapeutics (Chairman), Xenon Pharmaceuticals, Cantest, Allon Therapeutics, Providence Healthcare and Genome B.C. He was previously a Director of the British Columbia Biotechnology Association from 1992 to 1998. Mr. Holler received the BC Biotech Award for Vision and Leadership in 2003.

Mr. Holler holds a Masters of Business Administration degree and Bachelor of Arts (Economics) degree from the University of British Columbia.